Last update June 15, 2022

لوراسيدون

Compatible

Safe product and/or breastfeeding is the best option.

Atypical or second generation antipsychotic used in the treatment of schizophrenia and the depressive phase of bipolar disorder. Oral administration once daily.

It is excreted in breast milk in a clinically insignificant amount and no problems were observed in one infant whose mother was taking it. Plasma levels in that infant were very low. (Keightley 2020)  

Its pharmacokinetic data (very high percentage of protein binding, very large volume of distribution and moderately high molecular weight) explain the negligible passage into breast milk observed.

Lurasidone has little or no significant effect on prolactin levels. (Peuskens 2014) 

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.


See below the information of this related product:

Alternatives

  • Olanzapine (Safe product and/or breastfeeding is the best option.)
  • Quetiapine Fumarate (Safe product and/or breastfeeding is the best option.)
  • Risperidone (Safe product and/or breastfeeding is the best option.)
  • Ziprasidone (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

لوراسيدون is Lurasidone in Arabic.

Is written in other languages:

Groups

لوراسيدون belongs to these groups or families:

Tradenames

Main tradenames from several countries containing لوراسيدون in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. < 20 %
Molecular weight 529 daltons
Protein Binding 99 %
VD 88 l/Kg
pKa 8.5 -
Tmax 1 - 4 hours
18 - 37 hours
M/P ratio 4.4 -
Theoretical Dose 0.0024 mg/Kg/d
Relative Dose 0.44 %

References

  1. Keightley P, Schmidt Sotomayor N, O'Hara K, McWhinney B, Ungerer JP. Lurasidone in lactation: A case study with laboratory and clinical outcomes. Aust N Z J Psychiatry. 2020 Oct;54(10):1035-1036. Abstract
  2. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014 May;28(5):421-53. Abstract Full text (link to original source)

Total visits

618

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM